Cargando…

Treatment burden, adherence, and quality of life in children with daily GH treatment in France

OBJECTIVE: The objective of this study was to describe in a real-life setting the treatment burden and adherence and quality of life (QOL) of children treated with daily injections of growth hormone and their relationship with treatment duration. DESIGN: This non-interventional, multicenter, cross-s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coutant, Régis, Tauber, Maithé, Demaret, Béatrice, Henocque, Robin, Brault, Yves, Montestruc, François, Chassany, Olivier, Polak, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083659/ https://www.ncbi.nlm.nih.gov/pubmed/36866786 http://dx.doi.org/10.1530/EC-22-0464

Ejemplares similares

Yearly Height Gain Is Dependent on the Truly Received Dose of Growth Hormone and the Duration of Periods of Poor Adherence: Practical Lessons From the French Easypod™ Connect Multicenter Observational Study
por: Coutant, Régis, et al.
Publicado: (2022)

User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study
por: Tauber, Maithé, et al.
Publicado: (2013)

The burden and treatment of diabetes in France
por: Chevreul, Karine, et al.
Publicado: (2014)

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
por: Miller, Bradley S, et al.
Publicado: (2023)

Strategies to improve HIV treatment adherence in developed countries: clinical management at the individual level
por: Enriquez, Maithe, et al.
Publicado: (2011)

SUN-260 The Severity of GH Deficiency (GHD) Does Not Affect Adherence to Treatment in GHD Prepubertal Children Taking rh-GH via the Easypod Device
por: Loche, Sandro, et al.
Publicado: (2019)

Adherence to growth hormone (GH) therapy in naïve to treatment GH-deficient children: data of the Italian Cohort from the Easypod Connect Observational Study (ECOS)
por: Centonze, C., et al.
Publicado: (2019)

History of GH treatment in Japan
por: Tanaka, Toshiaki
Publicado: (2021)

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions
por: Adler, G, et al.
Publicado: (2014)

Approach to the Patient With Prader–Willi Syndrome
por: Höybye, Charlotte, et al.
Publicado: (2022)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Adherence to r-hGH Therapy in Pediatric Growth Hormone Deficiency: Current Perspectives on How Patient-Generated Data Will Transform r-hGH Treatment Towards Integrated Care
por: Savage, Martin O, et al.
Publicado: (2022)

No Improvement of Adult Height in Non-growth Hormone (GH) Deficient Short Children with GH Treatment
por: Tanaka, Toshiaki, et al.
Publicado: (2006)

The Relation of the White Blood Corpuscles to Suppurative Inflammation
por: Henocque, A.
Publicado: (1870)

More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children
por: Ciresi, Alessandro, et al.
Publicado: (2017)

Corrigendum to: “Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial”
Publicado: (2020)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

Correction to: “Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH”
Publicado: (2023)

Impact of Covid-19 on breast cancer stage at discovery, and time to treatment in Cote d’Or, France
por: Feron Agbo, Clémence, et al.
Publicado: (2023)

Factors Related to Quality of Life in Treatment-Adherent, Successfully Treated HIV Patients in France
por: Côté, José, et al.
Publicado: (2009)

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2023)

The household economic burden of eating disorders and adherence to treatment in Australia
por: Gatt, Lauren, et al.
Publicado: (2014)

Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation
por: Benzimra, Michaël, et al.
Publicado: (2018)

Cost-Utility of Acromegaly Pharmacological Treatments in a French Context
por: Brue, Thierry, et al.
Publicado: (2021)

Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency
por: Cohen-Barak, Orit, et al.
Publicado: (2015)

Corroboration of Height Velocity Prediction Markers for rhGH With an Oral GH Secretagogue Treatment in Children With GHD
por: Blum, Werner F, et al.
Publicado: (2021)

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
por: Otsuka, Fumio, et al.
Publicado: (2020)

Increased Secretion of Endogenous GH after Treatment with an Intranasal GH-releasing Peptide-2 Spray Does Not Promote Growth in Short Children with GH Deficiency
por: Tanaka, Toshiaki, et al.
Publicado: (2014)

Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet(®) IOS and Answer Program
por: Backeljauw, Philippe, et al.
Publicado: (2023)

Rectal Lymphogranuloma Venereum, France
por: Herida, Magid, et al.
Publicado: (2005)

Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV
por: Cohen, Calvin J, et al.
Publicado: (2013)

Estimating the burden of SARS-CoV-2 in France
por: Salje, Henrik, et al.
Publicado: (2020)

Growth Hormone (GH) Treatment Decreases Plasma Kisspeptin Levels in GH-Deficient Adults with Prader–Willi Syndrome
por: Giménez-Palop, Olga, et al.
Publicado: (2021)

Inside the Noonan “universe”: Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns
por: Stagi, Stefano, et al.
Publicado: (2022)

SAT643 Patient Preference Questionnaire Response After Switching To Somapacitan After Taking Daily Gh: 2-year Results From REAL4
por: Blair, Joanne, et al.
Publicado: (2023)

Regulation of GH and GH Signaling by Nutrients
por: Caputo, Marina, et al.
Publicado: (2021)

SAT-100 Trial-in-Progress: ZEPHYR, a Pivotal Phase 2b/3 Randomized, Placebo-Controlled Study of Livoletide, a Novel Unacylated Ghrelin Analog, for the Treatment of Hyperphagia and Food-Related Behaviors in Patients with Prader-Willi Syndrome
por: Allas, Soraya, et al.
Publicado: (2019)

Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet(®) IOS and ANSWER Program
por: Sävendahl, Lars, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kr73inkk893jmmbkpa68htt60h